Click here to get full coverage on FDA to review data on experimental Huntington's gene therapy at uniQure - Stock Titan

FDA to review data on experimental Huntington's gene therapy at uniQure  Stock Titan

FDA to review data on experimental Huntington's gene therapy at uniQure - Stock Titan

Click here to get full coverage on Is It Time To Reassess uniQure (QURE) After 83% One Year Share Price Gain? - simplywall.st

Is It Time To Reassess uniQure (QURE) After 83% One Year Share Price Gain?  simplywall.st

Is It Time To Reassess uniQure (QURE) After 83% One Year Share Price Gain? - simplywall.st

Click here to get full coverage on $QURE stock is up 17% today. Here's what we see in our data. - Quiver Quantitative

$QURE stock is up 17% today. Here's what we see in our data.  Quiver Quantitative

$QURE stock is up 17% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on This TikTok-Viral Microneedling System is 70% Off Right Now — and Worth Every Penny - Popsugar

This TikTok-Viral Microneedling System is 70% Off Right Now — and Worth Every Penny  Popsugar

This TikTok-Viral Microneedling System is 70% Off Right Now — and Worth Every Penny - Popsugar

Click here to get full coverage on uniQure: Now What? (NASDAQ:QURE) - Seeking Alpha

uniQure: Now What? (NASDAQ:QURE)  Seeking Alpha

uniQure: Now What? (NASDAQ:QURE) - Seeking Alpha

Click here to get full coverage on QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire

QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm  PR Newswire

QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire

Click here to get full coverage on QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP - Business Wire

QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP  Business Wire

QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP - Business Wire

Click here to get full coverage on Qure.ai and Microsoft Collaborate on Lung Cancer Detection - Inside Precision Medicine

Qure.ai and Microsoft Collaborate on Lung Cancer Detection  Inside Precision Medicine

Qure.ai and Microsoft Collaborate on Lung Cancer Detection - Inside Precision Medicine

Click here to get full coverage on uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval - GuruFocus

uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval  GuruFocus

uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval - GuruFocus

Click here to get full coverage on UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington’s Data Spurs Mizuho Downgrade and Delayed Launch - Yahoo Finance

UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington’s Data Spurs Mizuho Downgrade and Delayed Launch  Yahoo Finance

UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington’s Data Spurs Mizuho Downgrade and Delayed Launch - Yahoo Finance

Click here to get full coverage on uniQure gains as FDA sets up meeting on gene therapy (QURE:NASDAQ) - Seeking Alpha

uniQure gains as FDA sets up meeting on gene therapy (QURE:NASDAQ)  Seeking Alpha

uniQure gains as FDA sets up meeting on gene therapy (QURE:NASDAQ) - Seeking Alpha

Click here to get full coverage on uniQure Announces Type A Meeting Scheduled with FDA - GlobeNewswire

uniQure Announces Type A Meeting Scheduled with FDA  GlobeNewswire

uniQure Announces Type A Meeting Scheduled with FDA - GlobeNewswire

Click here to get full coverage on uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting - GuruFocus

uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting  GuruFocus

uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting - GuruFocus

Click here to get full coverage on uniQure N.V. (QURE): A Bear Case Theory - Yahoo Finance

uniQure N.V. (QURE): A Bear Case Theory  Yahoo Finance

uniQure N.V. (QURE): A Bear Case Theory - Yahoo Finance

Click here to get full coverage on Assessing uniQure (QURE) Valuation After FDA Setback On AMT-130 Approval Path - simplywall.st

Assessing uniQure (QURE) Valuation After FDA Setback On AMT-130 Approval Path  simplywall.st

Assessing uniQure (QURE) Valuation After FDA Setback On AMT-130 Approval Path - simplywall.st

Click here to get full coverage on What Do Analysts Think About UniQure (QURE)? - Yahoo Finance

What Do Analysts Think About UniQure (QURE)?  Yahoo Finance

What Do Analysts Think About UniQure (QURE)? - Yahoo Finance

Click here to get full coverage on uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Data Amid Regulatory Challenges - Yahoo Finance

uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Data Amid Regulatory Challenges  Yahoo Finance

uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Data Amid Regulatory Challenges - Yahoo Finance

Click here to get full coverage on A Beauty Editor Compares the Qure vs. Omnilux Red Light Therapy Mask - PureWow

A Beauty Editor Compares the Qure vs. Omnilux Red Light Therapy Mask  PureWow

A Beauty Editor Compares the Qure vs. Omnilux Red Light Therapy Mask - PureWow

Click here to get full coverage on TIME100 Most Influential Companies 2025: Qure.ai - Time Magazine

TIME100 Most Influential Companies 2025: Qure.ai  Time Magazine

TIME100 Most Influential Companies 2025: Qure.ai - Time Magazine

Click here to get full coverage on uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences - Yahoo Finance

uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences  Yahoo Finance

uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences - Yahoo Finance

Click here to get full coverage on Qure.ai CTA Tools Gets FDA Clearance - Diagnostic and Interventional Cardiology

Qure.ai CTA Tools Gets FDA Clearance  Diagnostic and Interventional Cardiology

Qure.ai CTA Tools Gets FDA Clearance - Diagnostic and Interventional Cardiology

Click here to get full coverage on UniQure N.V. (QURE) Stock Analysis: A Biotech Powerhouse With 137% Potential Upside - DirectorsTalk Interviews

UniQure N.V. (QURE) Stock Analysis: A Biotech Powerhouse With 137% Potential Upside  DirectorsTalk Interviews

UniQure N.V. (QURE) Stock Analysis: A Biotech Powerhouse With 137% Potential Upside - DirectorsTalk Interviews

Click here to get full coverage on uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates  Yahoo Finance

uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on uniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance

uniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release  Yahoo Finance

uniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance

Click here to get full coverage on Analysts Have Lowered Expectations For uniQure N.V. (NASDAQ:QURE) After Its Latest Results - Yahoo Finance

Analysts Have Lowered Expectations For uniQure N.V. (NASDAQ:QURE) After Its Latest Results  Yahoo Finance

Analysts Have Lowered Expectations For uniQure N.V. (NASDAQ:QURE) After Its Latest Results - Yahoo Finance

Click here to get full coverage on uniQure (QURE): Reassessing Valuation After FDA Doubts on AMT-130’s Path to Approval - Yahoo Finance

uniQure (QURE): Reassessing Valuation After FDA Doubts on AMT-130’s Path to Approval  Yahoo Finance

uniQure (QURE): Reassessing Valuation After FDA Doubts on AMT-130’s Path to Approval - Yahoo Finance

Click here to get full coverage on uniQure N.V. (QURE): A Bull Case Theory - Yahoo Finance

uniQure N.V. (QURE): A Bull Case Theory  Yahoo Finance

uniQure N.V. (QURE): A Bull Case Theory - Yahoo Finance

Click here to get full coverage on How (QURE) Movements Inform Risk Allocation Models - Stock Traders Daily

How (QURE) Movements Inform Risk Allocation Models  Stock Traders Daily

How (QURE) Movements Inform Risk Allocation Models - Stock Traders Daily

Click here to get full coverage on Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA - Yahoo Finance

Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA  Yahoo Finance

Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA - Yahoo Finance

Click here to get full coverage on uniQure (QURE) Is Up 9.4% After FDA Deems AMT-130 Phase I/II Data Inadequate for Filing - simplywall.st

uniQure (QURE) Is Up 9.4% After FDA Deems AMT-130 Phase I/II Data Inadequate for Filing  simplywall.st

uniQure (QURE) Is Up 9.4% After FDA Deems AMT-130 Phase I/II Data Inadequate for Filing - simplywall.st

Click here to get full coverage on H.C. Wainwright Raises the PT on uniQure N.V. (QURE), Keeps a Buy Rating - Yahoo Finance

H.C. Wainwright Raises the PT on uniQure N.V. (QURE), Keeps a Buy Rating  Yahoo Finance

H.C. Wainwright Raises the PT on uniQure N.V. (QURE), Keeps a Buy Rating - Yahoo Finance

Click here to get full coverage on Why uniQure (QURE) Is Up After Positive AMT-130 Trial Results and Major New Funding Announcements - Yahoo Finance

Why uniQure (QURE) Is Up After Positive AMT-130 Trial Results and Major New Funding Announcements  Yahoo Finance

Why uniQure (QURE) Is Up After Positive AMT-130 Trial Results and Major New Funding Announcements - Yahoo Finance

Click here to get full coverage on Summers Value Partners Established a Position in UniQure N.V. (QURE) in Q3 - Yahoo Finance

Summers Value Partners Established a Position in UniQure N.V. (QURE) in Q3  Yahoo Finance

Summers Value Partners Established a Position in UniQure N.V. (QURE) in Q3 - Yahoo Finance

Click here to get full coverage on uniQure N.V. (NASDAQ:QURE) Analysts Just Slashed Next Year's Revenue Estimates By 26% - Yahoo Finance

uniQure N.V. (NASDAQ:QURE) Analysts Just Slashed Next Year's Revenue Estimates By 26%  Yahoo Finance

uniQure N.V. (NASDAQ:QURE) Analysts Just Slashed Next Year's Revenue Estimates By 26% - Yahoo Finance

Click here to get full coverage on Qure.ai partners with Microsoft on lung cancer suite integration - AuntMinnie

Qure.ai partners with Microsoft on lung cancer suite integration  AuntMinnie

Qure.ai partners with Microsoft on lung cancer suite integration - AuntMinnie

Click here to get full coverage on uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission - Yahoo Finance

uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission  Yahoo Finance

uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission - Yahoo Finance

Click here to get full coverage on uniQure: Why Waiting For Clarity Beats Chasing The Next Step Jump (NASDAQ:QURE) - Seeking Alpha

uniQure: Why Waiting For Clarity Beats Chasing The Next Step Jump (NASDAQ:QURE)  Seeking Alpha

uniQure: Why Waiting For Clarity Beats Chasing The Next Step Jump (NASDAQ:QURE) - Seeking Alpha

Click here to get full coverage on Qure.ai Partners With Microsoft to Increase Access to Its Lung Cancer Detection and Management Suite in the U.S. - Business Wire

Qure.ai Partners With Microsoft to Increase Access to Its Lung Cancer Detection and Management Suite in the U.S.  Business Wire

Qure.ai Partners With Microsoft to Increase Access to Its Lung Cancer Detection and Management Suite in the U.S. - Business Wire

Click here to get full coverage on Indian healthcare AI startup Qure.AI aiming for IPO in two years, CEO says - Reuters

Indian healthcare AI startup Qure.AI aiming for IPO in two years, CEO says  Reuters

Indian healthcare AI startup Qure.AI aiming for IPO in two years, CEO says - Reuters

Click here to get full coverage on uniQure (QURE) Is Down 19.0% After FDA Questions Data for AMT-130 Gene Therapy Approval Pathway – Has The Bull Case Changed? - Yahoo Finance

uniQure (QURE) Is Down 19.0% After FDA Questions Data for AMT-130 Gene Therapy Approval Pathway – Has The Bull Case Changed?  Yahoo Finance

uniQure (QURE) Is Down 19.0% After FDA Questions Data for AMT-130 Gene Therapy Approval Pathway – Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on A Fresh Look at uniQure (QURE) Valuation Following Unexplained Share Price Move - Yahoo Finance

A Fresh Look at uniQure (QURE) Valuation Following Unexplained Share Price Move  Yahoo Finance

A Fresh Look at uniQure (QURE) Valuation Following Unexplained Share Price Move - Yahoo Finance

Click here to get full coverage on uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results - Yahoo Finance

uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results  Yahoo Finance

uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results - Yahoo Finance

Click here to get full coverage on $QURE stock is down 17% today. Here's what we see in our data. - Quiver Quantitative

$QURE stock is down 17% today. Here's what we see in our data.  Quiver Quantitative

$QURE stock is down 17% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on $QURE stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$QURE stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$QURE stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Mizuho Maintains uniQure N.V. (QURE) Outperform Recommendation - Nasdaq

Mizuho Maintains uniQure N.V. (QURE) Outperform Recommendation  Nasdaq

Mizuho Maintains uniQure N.V. (QURE) Outperform Recommendation - Nasdaq

Click here to get full coverage on U.S. Chess Champion is Bullish on these 3 Stocks – In-Demand QURE, Unsexy AMZN and Reliable BRK. - TipRanks

U.S. Chess Champion is Bullish on these 3 Stocks – In-Demand QURE, Unsexy AMZN and Reliable BRK.  TipRanks

U.S. Chess Champion is Bullish on these 3 Stocks – In-Demand QURE, Unsexy AMZN and Reliable BRK. - TipRanks

Click here to get full coverage on uniQure is Now Oversold (QURE) - Nasdaq

uniQure is Now Oversold (QURE) - Nasdaq

Click here to get full coverage on QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study - Yahoo Finance

QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study  Yahoo Finance

QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study - Yahoo Finance

Click here to get full coverage on Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington’s Disease - Yahoo Finance

Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington’s Disease  Yahoo Finance

Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington’s Disease - Yahoo Finance

Click here to get full coverage on News | decaturdailydemocrat.com - QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP - FinancialContent

News | decaturdailydemocrat.com - QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP  FinancialContent

News | decaturdailydemocrat.com - QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP - FinancialContent

Click here to get full coverage on Stifel Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq

Stifel Maintains uniQure N.V. (QURE) Buy Recommendation  Nasdaq

Stifel Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq

Click here to get full coverage on QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire

QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm  NewMediaWire

QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire

Click here to get full coverage on QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm - GlobeNewswire

QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm  GlobeNewswire

QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm - GlobeNewswire

Click here to get full coverage on $QURE stock is up 15% today. Here's what we see in our data. - Quiver Quantitative

$QURE stock is up 15% today. Here's what we see in our data.  Quiver Quantitative

$QURE stock is up 15% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on A Closer Look at uniQure (QURE) Valuation Following FDA Shift on Huntington’s Gene Therapy Data - Yahoo Finance

A Closer Look at uniQure (QURE) Valuation Following FDA Shift on Huntington’s Gene Therapy Data  Yahoo Finance

A Closer Look at uniQure (QURE) Valuation Following FDA Shift on Huntington’s Gene Therapy Data - Yahoo Finance

Click here to get full coverage on QURE Stock To $500? - Forbes

QURE Stock To $500? - Forbes

Click here to get full coverage on Population Health Management - Fierce Healthcare

Population Health Management  Fierce Healthcare

Population Health Management - Fierce Healthcare

Click here to get full coverage on I'm A Beauty Editor—My Favorite LED Face Mask Is 30% Off Before Prime Day Ends Tonight - Women's Health

I'm A Beauty Editor—My Favorite LED Face Mask Is 30% Off Before Prime Day Ends Tonight  Women's Health

I'm A Beauty Editor—My Favorite LED Face Mask Is 30% Off Before Prime Day Ends Tonight - Women's Health

Click here to get full coverage on $QURE stock is down 66% today. Here's what we see in our data. - Quiver Quantitative

$QURE stock is down 66% today. Here's what we see in our data.  Quiver Quantitative

$QURE stock is down 66% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on How Horizon Health and Qure.ai Are Using AI to Catch "Incidental" Lung Cancer - HIT Consultant

How Horizon Health and Qure.ai Are Using AI to Catch "Incidental" Lung Cancer  HIT Consultant

How Horizon Health and Qure.ai Are Using AI to Catch "Incidental" Lung Cancer - HIT Consultant

Click here to get full coverage on From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside (NASDAQ:QURE) - Seeking Alpha

From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside (NASDAQ:QURE)  Seeking Alpha

From Setback To Surge: UniQure's Huntington's Hope Is Poised For Upside (NASDAQ:QURE) - Seeking Alpha

Click here to get full coverage on Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength? - Nasdaq

Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength?  Nasdaq

Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength? - Nasdaq

Click here to get full coverage on UniQure Stock Plummets 52% on Potential FDA Decision. Here’s Why. - Barron's

UniQure Stock Plummets 52% on Potential FDA Decision. Here’s Why.  Barron's

UniQure Stock Plummets 52% on Potential FDA Decision. Here’s Why. - Barron's

Click here to get full coverage on Two Dutch hospitals implement AI for lung nodule detection on chest X-rays - healthcare-in-europe.com

Two Dutch hospitals implement AI for lung nodule detection on chest X-rays  healthcare-in-europe.com

Two Dutch hospitals implement AI for lung nodule detection on chest X-rays - healthcare-in-europe.com

Click here to get full coverage on Javier Zulueta named chief medical officer at Qure.ai - AuntMinnie

Javier Zulueta named chief medical officer at Qure.ai  AuntMinnie

Javier Zulueta named chief medical officer at Qure.ai - AuntMinnie

Click here to get full coverage on New Analyst Forecast: $QURE Given $33 Price Target - Quiver Quantitative

New Analyst Forecast: $QURE Given $33 Price Target  Quiver Quantitative

New Analyst Forecast: $QURE Given $33 Price Target - Quiver Quantitative

Click here to get full coverage on UniQure (QURE) stock drop looms as FDA concern over Huntington’s data spurs Mizuho downgrade and delayed launch - MSN

UniQure (QURE) stock drop looms as FDA concern over Huntington’s data spurs Mizuho downgrade and delayed launch  MSN

UniQure (QURE) stock drop looms as FDA concern over Huntington’s data spurs Mizuho downgrade and delayed launch - MSN

Click here to get full coverage on QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire

QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm  PR Newswire

QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire

QURE

Price Chart

Key Statistics

Technicals

About QURE

Latest News

FDA to review data on experimental Huntington's gene therapy at uniQure - Stock Titan

Is It Time To Reassess uniQure (QURE) After 83% One Year Share Price Gain? - simplywall.st

$QURE stock is up 17% today. Here's what we see in our data. - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers